Mortality
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
March BiosciencesTX - Houston
2 programsBirth Cohort in Coast Province, KenyaN/A1 trial
OPVN/A1 trial
Active Trials
NCT00625482Completed
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
March BiosciencesBirth Cohort in Coast Province, Kenya
March BiosciencesOPV
Essential PharmaceuticalsIMNCI
Clinical Trials (3)
Total enrollment: 66,883 patients across 3 trials
Birth Cohort in Coast Province, Kenya
Start: Jul 2015Est. completion: Apr 2016283 patients
N/ACompleted
Sex-Differential Health Interventions In Low-Birth-Weight Infants
Start: Feb 2008
N/ACompleted
Impact of the Integrated Management of Neonatal and Childhood Illness Strategy on Neonatal and Infant Mortality
Start: Jun 2006Est. completion: Apr 201066,600 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.